Abstract:The cholinergic nucleus basalis of Meynert, which is important for memory functions, shows neuronal activation ('up-phase') during the early stages of Alzheimer's disease and neurodegeneration ('down-phase') in later stages of Alzheimer's disease. MicroRNA-132 (miR-132) and the transcription factor early growth response-1 (EGR1) were proposed as possible candidate molecules regulating such an up-down activity pattern of the nucleus basalis of Meynert during the course of Alzheimer's disease, as they both show this up-down pattern of expression in the prefrontal cortex during the course of Alzheimer's disease. Not only do these two molecules stimulate synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In the nucleus basalis of Meynert, we investigated the expression of miR-132 and EGR1 along the entire course of Alzheimer's disease. Forty-nine post-mortem nucleus basalis of Meynert samples were studied, ranging from non-demented controls (Braak stage = 0) to late Alzheimer's disease patients (Braak stage = VI), and from clinical Reisberg scale 1 to 7. Each Braak stage contained seven samples, that were all well matched for confounding factors, i.e. age (range 58-91), sex, post-mortem delay, cerebrospinal fluid pH (as a measure for agonal state), APOE genotype, clock time of death, tissue fixation time, and tissue storage time. The alterations of these two molecules were studied over the course of Alzheimer's disease in relation to the expression of 4G8-stained amyloid-β, hyperphosphorylated tau stained by antibody AT8, neuronal fibrillary tangles and neuropil threads stained by silver, and in relation to alterations in choline acetyltransferase. We found that the expression of miR-132 and EGR1 in the nucleus basalis of Meynert was quite stable during the early stages of Alzheimer's disease and decreased significantly only during late Alzheimer's disease stages. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression (r = 0.49, P < 0.001 and r = 0.61, P < 0.001), while choline acetyltransferase expression showed a significantly negative correlation with hyperphosphorylated tau (r = -0.33, P = 0.021) but no correlation with 4G8-stained amyloid-β. From the functional changes of miR-132 and EGR1 along the course of Alzheimer's disease we conclude: (i) that these two molecules may play a role in keeping the cholinergic function intact in early Alzheimer's disease stages; and (ii) that these molecules may contribute to the late neurodegeneration of this cholinergic nucleus.

Degeneration in Nucleus basalis of Meynert signals earliest stage of Alzheimer's disease progression

Degeneration in Nucleus basalis of Meynert signals earliest stage of Alzheimer's disease progression

Lateral thinking: Neurodegeneration of the cortical cholinergic system in Alzheimer's disease

Lateral Thinking: Pathway Specific Neurodegeneration of the Cortical Cholinergic System in Alzheimer's Disease

Nucleus Basalis of Meynert degeneration predicts cognitive decline in Corticobasal Syndrome

Degeneration of cholinergic white matter pathways and nucleus basalis of Meynert in individuals with objective subtle cognitive impairment

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Loss of Synaptic Density in Nucleus Basalis of Meynert Indicates Distinct Neurodegeneration in Alzheimer’s Disease: the RJNB-D Study

Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer's disease: the RJNB-D study

Increased Functional Connectivity Between Nucleus Basalis of Meynert and Amygdala in Cognitively Intact Elderly along the Alzheimer’s Continuum

Progression of hippocampal subfield atrophy and asymmetry in Alzheimer's disease

Regional transcriptional vulnerability to basal forebrain functional dysconnectivity in mild cognitive impairment patients

Gray matter structural covariance networks changes along the Alzheimer's disease continuum.

The degeneration of locus coeruleus occurring during Alzheimer's disease clinical progression: a neuroimaging follow-up investigation

Altered multimodal magnetic resonance parameters of basal nucleus of Meynert in Alzheimer’s disease

Longitudinal Trajectory of Amyloid-related Hippocampal Subfield Atrophy in Nondemented Elderly.

Meynert Nucleus-Related Cortical Thinning in Parkinson's Disease with Mild Cognitive Impairment.

“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer’s Disease Progression

Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease

MicroRNA-132 and Early Growth Response-1 in Nucleus Basalis of Meynert During the Course of Alzheimer’s Disease

A model of brain morphological changes related to aging and Alzheimer's disease from cross-sectional assessments